Importance of Early Insulin Secretion
Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
- Priscilla A. Hollander, MD, PHD1,
- Sherwyn L. Schwartz, MD2,
- Marjorie R. Gatlin, MD3,
- Stephen J. Haas, BS3,
- Hongjie Zheng, BS3,
- James E. Foley, PHD3 and
- Beth E. Dunning, PHD3
- 1Ruth Collins Diabetes Center, Baylor University Medical Center, Dallas, Texas
- 2Diabetes and Glandular Disease Clinic, San Antonio, Texas
- 3Novartis Pharmaceuticals, East Hanover, New Jersey
Abstract
OBJECTIVE—This study compared the effects of nateglinide, glyburide, and placebo on postmeal glucose excursions and insulin secretion in previously diet-treated patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—This randomized, double-blind, placebo-controlled multicenter study was conducted in 152 patients who received either nateglinide (120 mg before three meals daily, n = 51), glyburide (5 mg q.d. titrated to 10 mg q.d. after 2 weeks, n = 50), or placebo (n = 51) for 8 weeks. Glucose, insulin, and C-peptide profiles during liquid meal challenges were measured at weeks 0 and 8. At weeks −1 and 7, 19-point daytime glucose and insulin profiles, comprising three solid meals, were measured.
RESULTS—During the liquid-meal challenge, nateglinide reduced the incremental glucose area under the curve (AUC) more effectively than glyburide (Δ = −4.94 vs. −2.71 mmol · h/l, P < 0.05), whereas glyburide reduced fasting plasma glucose more effectively than nateglinide (Δ = −2.9 vs. −1.0 mmol/l, respectively, P < 0.001). In contrast, C-peptide induced by glyburide was greater than that induced by nateglinide (Δ = +1.83 vs. +0.95 nmol · h/l, P < 0.01), and only glyburide increased fasting insulin levels. During the solid meal challenges, nateglinide and glyburide elicited similar overall glucose control (Δ 12-h incremental AUC = −13.2 vs. −15.3 mmol · h/l), but the insulin AUC induced by nateglinide was significantly less than that induced by glyburide (Δ 12-h AUC = +866 vs. +1,702 pmol · h/l, P = 0.01).
CONCLUSIONS—This study demonstrated that nateglinide selectively enhanced early insulin release and provided better mealtime glucose control with less total insulin exposure than glyburide.
Footnotes
-
Address correspondence and reprint requests to Priscilla A. Hollander, MD, PhD, 3600 Gaston Avenue, Dallas, TX 75246. E-mail: priscilh{at}baylordallas.edu.
Received for publication 8 September 2000 and accepted in revised form 2 January 2001.
B.E.D. and H.Z. were formerly employed by Novartis Pharmaceuticals; M.J.G., J.E.F., and S.J.H. are currently employed by Novartis Pharmaceuticals. P.A.H. is a member of the advisory panel and has been a speaker and consultant for Novartis Pharmaceuticals. The laboratory in which S.S. works is funded by Abbott, Asta Medica, Merck, Parke-Davis, Pfizer, Sanwa, and Sepracor.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
